Table 1. Clinical characteristics of the patients and univariate survival analysis.
| All patients | Survival | |||
|---|---|---|---|---|
| Characteristic | (N=96) | Univariate analysis | ||
| Age--no. | p=0.03 | |||
| ≤50 years | 28 | |||
| >50 years | 68 | |||
| Sex--no. | NS | |||
| Male | 51 | |||
| Female | 45 | |||
| Preoperative KPS performance status –no. | NS | |||
| ≤ 70 | 44 | |||
| > 70 | 46 | |||
| ND | 6 | |||
| Extent of surgery — no. | NS | |||
| Debulking | ||||
| Partial resection | 25 | |||
| Complete resection | 67 | |||
| ND | 4 | |||
| Treatment(*)—no. | p=0.01 | |||
| None | 2 | |||
| Radiotherapy alone | 16 | |||
| Chemotherapy alone | 3 | |||
| Radiotherapy plus chemotherapy | ||||
| Temozolomide | 35 | |||
| PCV | 16 | |||
| Other | 22 | |||
| ND | 2 | |||
| Findings on pathological review — no. | p = 6 x 10-5 | |||
| WHO grade IV (GBM) | 64 | |||
| WHO grade III (24 AA and 8 AO) | 32 | |||
| Cytoplasmic EDNRB - (%) | p < 0.001 | |||
| Median | 81 | |||
| Range | 12--100 | |||
| Nuclear p60/CAF-1 – (%) | p < 0.001 | |||
| Median | 25 | |||
| Range | 4--60 | |||
| Nuclear HJURP - (%) | p=0.002 | |||
| Median | 10 | |||
| Range | 0--34 | |||
| Cytoplasmic PDLI4 - (%) | p=0.11 | |||
| Median | 50 | |||
| Range | 4--91 | |||
| Survival -- months | ||||
| Median | 16 | |||
| 95CI | 14-19.1 | |||
(*)
PCV consists of three chemotherapy drugs: procarbazine, CCNU and vincristine. Other: includes topotecan, BCNU, Gemini and 8-drug chemotherapy